An exceptional outcome that must not become an exception

The decision to streamline the new listings of two BMS immunotherapies represents a rare moment of common sense. By trusting clinicians and using risk-sharing to manage costs, the move replaces years of bureaucratic complexity with a rational pathway. Yet its lasting impact depends on whether stakeholders work to turn a bold exception into a new standard. …